Alnylam and Regeneron unveil RNAi partnership

Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference (RNAi) therapeutics.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Regeneron forms consortium to fund exome sequencing

12 January 2018 Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.

Biotechnology

Regeneron sued over antibody protein used to treat Trump’s COVID-19 symptoms

6 October 2020 Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.

Big Pharma

A deep dive into Regeneron v Kymab

8 March 2021 On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.

More on this story

Europe

Regeneron forms consortium to fund exome sequencing

12 January 2018 Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.

Biotechnology

Regeneron sued over antibody protein used to treat Trump’s COVID-19 symptoms

Big Pharma

A deep dive into Regeneron v Kymab

8 March 2021 On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.

More on this story

Europe

Regeneron forms consortium to fund exome sequencing

12 January 2018 Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.

Biotechnology

Regeneron sued over antibody protein used to treat Trump’s COVID-19 symptoms

Big Pharma

A deep dive into Regeneron v Kymab

8 March 2021 On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.